Evaluation of the Efficacy of Early Implantation of a Percutaneous Left Ventricular Assist Devices in Acute Coronary Syndrome Complicated by Cardiogenic Shock Compared to Conventional Therapy: a Prospective, Multicenter, Randomized, Controlled and Open-label Clinical Trial

NARecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

December 19, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Cardiogenic Shock
Interventions
DEVICE

IMPELLA CP

Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT \>250 s. As soon as the device is in place it will be started.

OTHER

Conventional therapy

The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.

Trial Locations (1)

13354

RECRUITING

Assistance Publique Hopitaux de Marseille, Marseille

All Listed Sponsors
lead

Assistance Publique Hopitaux De Marseille

OTHER